BACKGROUND: Natural killer (NK) cells likely contribute to outcome of acute hepatitis C virus (HCV) infection and interferon (IFN)-induced control of chronic HCV infection. We previously observed IFN-αR and NKp30 expression associated with IFN-α-dependent NK cell activity. METHODS: Here, we examined CD16(+)56(-), CD16(+)56(+), and CD16(-)56(+) NK cell subset IFN-αR and NKp30 expression in relation to magnitude of HCV genotype 1 decrease during pegylated IFN-α plus ribavirin therapy. RESULTS: We observed greater baseline IFN-αR and NKp30 expression on CD16(+)56(+) and CD16(-)56(+) NK subsets in HCV-infected patients than in healthy control subjects. Baseline CD16(+)56(-) NK IFN-αR expression was associated with IFN-α-induced pSTAT1, and both were associated with magnitude of HCV decrease during pegylated IFN-α plus ribavirin therapy. Baseline CD16(+)56(-) NK IFN-αR expression was associated with race and interleukin 28B genotype, negatively associated with aspartate aminotransferase-to platelet ratio index, and positively associated with increase in NKp30 expression after in vivo IFN-α exposure. Finally, in vitro IFN-α2a-activated NK cytolysis of HCV-infected target cells was in part dependent on NKp30, and CD16(+)56(-) NK cell IFN-αR expression correlated with cytolytic activity. CONCLUSIONS: IFN-αR expression on CD16(+)56(-) NK cells during chronic HCV infection may in part be genetically determined, and level of expression regulates IFN-α signaling, which in turn may contribute to control of HCV infection.
BACKGROUND: Natural killer (NK) cells likely contribute to outcome of acute hepatitis C virus (HCV) infection and interferon (IFN)-induced control of chronic HCV infection. We previously observed IFN-αR and NKp30 expression associated with IFN-α-dependent NK cell activity. METHODS: Here, we examined CD16(+)56(-), CD16(+)56(+), and CD16(-)56(+) NK cell subset IFN-αR and NKp30 expression in relation to magnitude of HCV genotype 1 decrease during pegylated IFN-α plus ribavirin therapy. RESULTS: We observed greater baseline IFN-αR and NKp30 expression on CD16(+)56(+) and CD16(-)56(+) NK subsets in HCV-infectedpatients than in healthy control subjects. Baseline CD16(+)56(-) NK IFN-αR expression was associated with IFN-α-induced pSTAT1, and both were associated with magnitude of HCV decrease during pegylated IFN-α plus ribavirin therapy. Baseline CD16(+)56(-) NK IFN-αR expression was associated with race and interleukin 28B genotype, negatively associated with aspartate aminotransferase-to platelet ratio index, and positively associated with increase in NKp30 expression after in vivo IFN-α exposure. Finally, in vitro IFN-α2a-activated NK cytolysis of HCV-infected target cells was in part dependent on NKp30, and CD16(+)56(-) NK cell IFN-αR expression correlated with cytolytic activity. CONCLUSIONS: IFN-αR expression on CD16(+)56(-) NK cells during chronic HCV infection may in part be genetically determined, and level of expression regulates IFN-α signaling, which in turn may contribute to control of HCV infection.
Authors: Kerstin A Stegmann; Niklas K Björkström; Heike Veber; Sandra Ciesek; Peggy Riese; Johannes Wiegand; Johannes Hadem; Pothakamuri V Suneetha; Jerzy Jaroszewicz; Chun Wang; Verena Schlaphoff; Paraskevi Fytili; Markus Cornberg; Michael P Manns; Robert Geffers; Thomas Pietschmann; Carlos A Guzmán; Hans-Gustaf Ljunggren; Heiner Wedemeyer Journal: Gastroenterology Date: 2010-02-02 Impact factor: 22.682
Authors: Veronica D Gonzalez; Karolin Falconer; Niklas K Björkström; Kim G Blom; Ola Weiland; Hans-Gustaf Ljunggren; Annette Alaeus; Johan K Sandberg Journal: J Immunol Date: 2009-10-21 Impact factor: 5.422
Authors: Alexander J Thompson; Andrew J Muir; Mark S Sulkowski; Dongliang Ge; Jacques Fellay; Kevin V Shianna; Thomas Urban; Nezam H Afdhal; Ira M Jacobson; Rafael Esteban; Fred Poordad; Eric J Lawitz; Jonathan McCone; Mitchell L Shiffman; Greg W Galler; William M Lee; Robert Reindollar; John W King; Paul Y Kwo; Reem H Ghalib; Bradley Freilich; Lisa M Nyberg; Stefan Zeuzem; Thierry Poynard; David M Vock; Karen S Pieper; Keyur Patel; Hans L Tillmann; Stephanie Noviello; Kenneth Koury; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; David B Goldstein; John G McHutchison Journal: Gastroenterology Date: 2010-04-24 Impact factor: 22.682
Authors: Sara J Conry; Kimberly A Milkovich; Nicole L Yonkers; Benigno Rodriguez; Helene B Bernstein; Robert Asaad; Frederick P Heinzel; Magdalena Tary-Lehmann; Michael M Lederman; Donald D Anthony Journal: J Virol Date: 2009-08-19 Impact factor: 5.103
Authors: J R Vidal-Castiñeira; A López-Vázquez; R Díaz-Peña; R Alonso-Arias; J Martínez-Borra; R Pérez; J Fernández-Suárez; S Melón; J Prieto; L Rodrigo; C López-Larrea Journal: J Virol Date: 2010-01 Impact factor: 5.103
Authors: Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George Journal: Nat Genet Date: 2009-09-13 Impact factor: 38.330
Authors: E Papasavvas; L Azzoni; X Yin; Q Liu; J Joseph; A Mackiewicz; B Ross; K M Lynn; J M Jacobson; K Mounzer; J R Kostman; L J Montaner Journal: J Viral Hepat Date: 2017-05-11 Impact factor: 3.728
Authors: Qinglai Meng; M R Sandhya Rani; Julia M Sugalski; Chelsey J Judge; Sarah Phat; Benigno Rodriguez; Ronald E Blanton; Donald D Anthony Journal: J Infect Dis Date: 2013-12-02 Impact factor: 5.226
Authors: Donald D Anthony; Sara J Conry; Kathy Medvik; M R Sandhya Rani; Yngve Falck-Ytter; Ronald E Blanton; Michael M Lederman; Benigno Rodriguez; Alan L Landay; Johan K Sandberg Journal: J Infect Dis Date: 2012-07-10 Impact factor: 7.759